Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

S. Nagase



Author of

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-006 - Examination of recurrence predictors in cases receiving UFT as postoperative adjuvant chemotherapy for lung cancer (ID 658)

      09:30 - 09:30  |  Author(s): S. Nagase

      • Abstract

      Background
      Although the 2012 version of the clinical practice guidelines for lung cancer published by the Japan Lung Cancer Society recommends performing a tegafur-uracil (UFT) compound drug therapy on cases of non-small cell lung cancer for stage 1A and 1B tumors measuring > 2 cm in diameter after surgery, we often encounter cases of recurrence. Therefore, we obtained data on T2a tumors (> 3 cm but < 5 cm in diameter) treated with UFT as postoperative adjuvant chemotherapy at our hospital and examined their recurrence predictors.

      Methods
      Among 2,724 cases of total surgical removal of non-small cell lung cancer performed between January 1997 and December 2007, we examined 168 cases with stage 1B T2a tumors treated with UFT to clarify the recurrence predictors in these cases. We examined age, sex, tumor diameter, vascular invasion, lymphatic involvement, pleural invasion, histologic degree of differentiation, tissue, and CEA.

      Results
      The age range was 38 to 85 years (median 66 years), and there were 108 men and 60 women. The 5-year recurrence-free survival rate was 72.7%. In cases of recurrence, the median time to recurrence was 662 days in 48 of the 168 cases (28.6%). On univariate analysis, vascular invasion (p < 0.001), male sex (p = 0.045), and non-differentiation (p < 0.002) were identified as significant recurrence predictors. On multivariate analysis, vascular invasion (p = 0.009) was found to be a significant recurrence predictors. Please confirm this part as the changes were made based on the original Japanese text.

      Conclusion
      It was inferred that vascular invasion is a primary recurrence predictor in cases receiving UFT as postoperative adjuvant chemotherapy. We need to consider a more careful follow-up during UFT administration as postoperative adjuvant chemotherapy in stage 1B T2a tumors.

  • +

    P3.10 - Poster Session 3 - Chemotherapy (ID 210)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P3.10-033 - Prognostic factors in stage III non-small cell lung cancer patients with postoperative brain metastases (ID 2084)

      09:30 - 09:30  |  Author(s): S. Nagase

      • Abstract

      Background
      The brain is the most frequent site of distant metastases in patients with non-small cell lung cancer (NSCLC). In stages I-IIIA NSCLC, after complete resection of the primary tumor, brain metastases account for 9.4% to 36.8% of all recurrences. This study assessed the risk factors for brain metastasis and the prognostic factors for survival after brain recurrence in patients whose advanced NSCLC was resected.

      Methods
      A total of 101 patients with brain metastases occurring after resection of stage III NSCLC tumors at Tokyo Medical University Hospital between 1995 and 2010 were retrospectively reviewed.

      Results
      The median time to onset of brain metastasis was 11.2 months (1-72 months) and the median survival time from the diagnosis of brain metastasis was 18.5 months (1-60 months). Multivariate analysis revealed that the risk factors for brain metastasis in postoperative stage III NSCLC included the following parameters: adenocarcinoma,age <65 years at recurrence, N2-N3, incomplete resection, and vascular invasion. In addition, the significant favorable prognostic factors included the absence of neurologic signs and symptoms, single and small size of brain metastasis, age <65, and treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

      Conclusion
      It was possible to identify patientsat high-risk for brain metastases after surgery. For these patients, careful follow-up is needed after surgery. It is important to detect brain recurrence in patients with NSCLC before neurologic signs or symptoms develop, as early detection improves prognosis.

  • +

    P3.24 - Poster Session 3 - Supportive Care (ID 160)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Supportive Care
    • Presentations: 1
    • +

      P3.24-014 - Multicenter study of zoledronic acid in lung cancer patients with bone metastasis. Thoracic Oncology Research Group (TORG) 1017. (ID 1043)

      09:30 - 09:30  |  Author(s): S. Nagase

      • Abstract

      Background
      Bone is the most frequent site of metastasis for lung cancer, and metastatic bone disease causes pain. Furthermore, bone metastasis may produce skeletal-related events (SREs) that greatly reduce quality of life and may even lead to death. Several guidelines have recommended use of bone-modifying agents (BMA) such as zoledronic acid (ZA) at the first diagnosis of bone metastases in patients with solid tumors, continued every 3-4 weeks as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. However, due to the risk of osteonecrosis of the jaw (ONJ) and a perceived lack of evidence for reduced SRE in lung cancer, some physicians have hesitated to administer ZA in lung cancer patients with bone metastasis. Therefore, the main objective of the present study was both to describe real world data of ZA and to compare SREs among previous reports.

      Methods
      All patients with non-small cell lung cancer (NSCLC) accompanied by metastatic bone disease (MBD) who were administered ZA at least twice from 12 hospitals in the TORG in Japan between January 2008 and December 2009 were eligible for inclusion in the study.

      Results
      A total of 198 consecutive patients (126 men, 72 women; median age, 64 years; range, 44-89 years) were identified. Histological type was as follows: adenocarcinoma (n=131, 66%); squamous cell carcinoma (n=30, 15%); and others (n=37, 19%). About two-thirds of patients experienced SRE before starting anti-cancer therapy. Median duration of ZA administration was 106 days (range, 28-1126 days), and median number of ZA administrations was four (range, 2-41). Median time to first SRE in patients who experienced SRE after treatment was 202 days (range, 156-264 days). No ONJ was reported from the 198 patients.

      Conclusion
      We found that ZA was not used sufficiently in clinical practice in Japan. Our data suggest that ONJ during the treatment of lung cancer patients is very rare, and ZA is potentially useful in lung patients with bone metastasis.